LYEL_OUT_1 [2025-03-19 11:56:52 -0400] 2323 Bytes | 660 tokens | Cum: 660 tkns (8.25% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Lyell Immunopharma (LYEL) which is at 0.58 up from 0.4837. So, I pulled together a bunch of data for you to look over real fast. It's still early, 11:56:51 AM on Wednesday March 19, 2025 ET (UTC-0400). So, what's the verdict? You're the expert!

Here's the first list of news for Lyell Immunopharma:

C1 - Mar-11-25 04:05PM - Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
C2 - Feb-18-25 04:05PM - Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
C3 - Jan-22-25 12:00PM - Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why
C4 - Jan-09-25 09:00AM - Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
C5 - Dec-31-24 09:35AM - After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
C6 - Dec-30-24 09:35AM - After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
C7 - Dec-13-24 09:35AM - Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
C8 - Dec-09-24 09:00PM - Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Lyell Immunopharma (LYEL)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Lyell Immunopharma.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

LYEL_OUT_3 [2025-03-19 11:56:57 -0400] 971 Bytes | 276 tokens | Cum: 938 tkns (11.72% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024**
Date: Mar-11-25 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/11/3040985/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2024.html

March 11, 2025 16:05 ET| Source:Lyell Immunopharma, IncLyell Immunopharma, Inc

SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2024.

“Last year was transformative for Lyell and now, based on promising emerging clinical data, we are poised to initiate pivotal deve

-- More? (MOR) or Next section? (NEX)

LYEL_OUT_5 [2025-03-19 11:56:59 -0400] 951 Bytes | 272 tokens | Cum: 1213 tkns (15.16% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T00:18:44Z - Lyell Immunopharma director Richard Klausner purchases $94,942 in stock By Investing.com...
A2 - 2025-03-18T23:06:07Z - Lyell Immunopharma CFO Newton purchases $111,620 in common stock By Investing.com...
A3 - 2025-03-18T23:05:47Z - Lyell Immunopharma CFO Newton purchases $111,620 in common stock By Investing.com...
A4 - 2025-03-18T23:06:07Z - Lyell Immunopharma CFO Newton purchases $111,620 in common stock By Investing.com...
A5 - 2025-03-18T23:06:07Z - Lyell Immunopharma CFO Newton purchases $111,620 in common stock By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

LYEL_OUT_7 [2025-03-19 11:57:00 -0400] 967 Bytes | 264 tokens | Cum: 1479 tkns (18.49% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Lyell Immunopharma director Richard Klausner purchases $94,942 in stock By Investing.com**Date: 2025-03-19Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/insider-trading-news/lyell-immunopharma-director-richard-klausner-purchases-94942-in-stock-93CH-3935743Richard Klausner, a director at Lyell Immunopharma , Inc. (NASDAQ:LYEL), recently acquired 158,000 shares of the company's common stock. The shares were purchased on March 14 at a weighted average price of $0.6009, with the total transaction valued at approximately $94,942. The purchase comes as LYEL shares trade near their 52-week low of $0.48, having declined nearly 28% in the past week alone. InvestingPro data shows the stock has fallen about 69% over the past six months.

This acquisition increased Klausner's total direct and indirect holdings to 3,812,199 shar

-- More? (MOR) or Next section? (NEX)

LYEL_OUT_9 [2025-03-19 11:57:02 -0400] 1135 Bytes | 330 tokens | Cum: 1811 tkns (22.64% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-10-24T20:00:00Z - Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
B2 - 2024-10-04T13:00:00Z - Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
B3 - 2024-07-08T17:02:50Z - Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire
B4 - 2024-06-26T11:00:00Z - Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
B5 - 2024-06-03T20:05:00Z - Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
B6 - 2024-04-16T10:53:41Z - Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LYEL_OUT_11 [2025-03-19 11:57:09 -0400] 755 Bytes | 199 tokens | Cum: 2012 tkns (25.15% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/24/10/g41529414/lyell-immunopharma-to-acquire-immpact-bio-and-prioritizes-its-pipeline-to-focus-on-next-generationLyell Immunopharma announced the acquisition of ImmPACT Bio, a clinical-stage biotechnology company, to strengthen its pipeline of next-generation CAR T-cell therapies. Lyell will prioritize the development of ImmPACT's lead program, IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate, and discontinue the development of some of its own programs.

-- More? (MOR) or Next section? (NEX)

LYEL_OUT_13 [2025-03-19 11:57:11 -0400] 826 Bytes | 209 tokens | Cum: 2357 tkns (29.46% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S4 - 2025-03-11 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited CONS financial statements and the related ...

S5 - 2025-03-11 8-K Item 2.02 Results of Oper and Fin Cond.

On March 11, 2025, Lyell Immunopharma, Inc. (the Company) issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. A copy of the press release is attached hereto as Ex...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

LYEL_OUT_15 [2025-03-19 11:57:17 -0400] 967 Bytes | 178 tokens | Cum: 2537 tkns (31.71% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report on Form 10-K contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives and expectations for our business. Our actual results and the timing of selected events could differ materially from those described in or implied by these forward-looking statements as a result of several factors,

-- More? (MOR) or Next section? (NEX)

LYEL_OUT_17 [2025-03-19 11:57:33 -0400] 6340 Bytes | 1642 tokens | Cum: 4334 tkns (54.17% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+--------------------+-----------------------+-------------------------+----------------------------+------------------------+
| Prev Close: 0.48 | RSI (14): 43.93 | Perf Quarter: -14.50% | Insider Trans: 0.32% | Sales Q/Q: -15.38% | ROE: -66.10% |
+--------------------+--------------------+-----------------------+-------------------------+----------------------------+------------------------+
| Target Price: 0.80 | ATR (14): 0.07 | Index: RUT | Option/Short: Yes / Yes | Sales past 5Y: 332.01% | ROI: -79.06% |
+--------------------+--------------------+-----------------------+-------------------------+----------------------------+------------------------+
| Price: 0.58 | SMA20: -12.24% | Market Cap: 170.08M | Short Float: 6.44% | Income: -342.99M | Sales Surprise: - |
+--------------------+--------------------+-----------------------+-------------------------+----------------------------+------------------------+
| Change: 19.10% | SMA50: -7.01% | Shs Outstand: 294.88M | Short Ratio: 7.49 | Employees: 300 | EPS Surprise: -314.71% |
+--------------------+--------------------+-----------------------+-------------------------+----------------------------+------------------------+
| Volume: 1,571,758 | SMA200: -50.83% | Shs Float: 125.61M | Short Interest: 8.09M | Debt/Eq: 0.15 | P/E: - |
+--------------------+--------------------+-----------------------+-------------------------+----------------------------+------------------------+
| Avg Volume: 1.08M | Perf Week: -14.21% | Inst Own: 22.48% | Beta: -0.22 | Sales Y/Y TTM: -53.08% | Earnings: Mar 12 BMO |
+--------------------+--------------------+-----------------------+-------------------------+----------------------------+------------------------+
| Rel Volume: 3.94 | Perf Month: -5.46% | Insider Own: 57.45% | Sales: 0.06M | Profit Margin: -562285.25% | |
+--------------------+--------------------+-----------------------+-------------------------+----------------------------+------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: Lyell Immunopharma, Inc. (LYEL) by Seely Lynn (President and CEO) on 2025-03-14
- Common Stock: 175000 shares at $0.6068 (D)

Inside Trans: Lyell Immunopharma, Inc. (LYEL) by Newton Charles W. (Chief Financial Officer) on 2025-03-17
- Common Stock: 200000 shares at $0.5581 (I)

Inside Trans: Lyell Immunopharma, Inc. (LYEL) by Klausner Richard (Unknown Title) on 2025-03-14
- Common Stock: 158000 shares at $0.6009 (I)

Inside Trans: Lyell Immunopharma, Inc. (LYEL) by Lee Gary K. (Chief Scientific Officer) on 2025-02-10
- Common Stock: 112500 shares at $0 (D) Footnote: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
- Option (right to buy): 450000 shares at $0 (D)
- Option (right to buy): 56250 shares at $0 (D)

Inside Trans: Lyell Immunopharma, Inc. (LYEL) by Newton Charles W. (Chief Financial Officer) on 2025-02-10
- Common Stock: 112500 shares at $0 (D) Footnote: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting
date
- Option (right to buy): 450000 shares at $0 (D)
- Option (right to buy): 56250 shares at $0 (D)

Inside Trans: Lyell Immunopharma, Inc. (LYEL) by Hill Stephen J. (Chief Operating Officer) on 2025-02-10
- Common Stock: 112500 shares at $0 (D) Footnote: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
- Option (right to buy): 450000 shares at $0 (D)
- Option (right to buy): 56250 shares at $0 (D)

Inside Trans: Lyell Immunopharma, Inc. (LYEL) by Seely Lynn (President and CEO) on 2025-02-10
- Common Stock: 337500 shares at $0 (D) Footnote: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
- Option (right to buy): 1350000 shares at $0 (D)
- Option (right to buy): 168750 shares at $0 (D)

Inside Trans: Lyell Immunopharma, Inc. (LYEL) by Lang Matthew (Chief Business Officer) on 2025-02-10
- Common Stock: 112500 shares at $0 (D) Footnote: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting
date.
- Option (right to buy): 450000 shares at $0 (D)
- Option (right to buy): 56250 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

LYEL_OUT_19 [2025-03-19 11:57:34 -0400] 561 Bytes | 131 tokens | Cum: 4827 tkns (60.34% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More financial metrics
-> X3 <- More SEC filings & insider data
-> X4 <- Broader sector & market news
-> X5 <- General market sentiment & AI confidence levels
-> X6 <- AI's past analysis on similar companies
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

LYEL_IN_21 [2025-03-19 11:57:35 -0400] 126 Bytes | 29 tokens | Cum: 4863 tkns (60.79% of 8k)
==========================================================================

====================================
[2025-03-19 08:57:35] # Analysis Completed
Elapsed Time: 44.34 seconds